Search

Multiple Myeloma

The SWG Multiple Myeloma has traditionally been composed of members of the European Myeloma Network (EMN). EMN is a dedicated academic, non-profit organization for clinical research in multiple myeloma.

Read more

Recommendation for hematologists in COVID-19 crisis

Recommendations for hematologists in COVID-19 crisis
COVID-19, caused by SARS-CoV-2, is expected to be a devastating infection in patients with active cancer. It should be taken seriously and managed rigorously without jeopardizing the curative chance of individual cancer patients.

Read more

Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.

 

Abstract S722
Acute lymphoblastic leukemia  (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Research

Research in hematology has dramatically improved our understanding of hematologic diseases and resulted in many innovative, groundbreaking discoveries.

Read more

Secure European Research Funding! Sign the Petition!

 

http://www. no-cuts-on-research. eu
EHA supports European Nobel and Fields Medal prizewinners to prevent the EU research funding for 2014-2020 from being subject to budget cuts.

Read more